- Home
- NBIX vs JEF Comparison
NBIX vs JEF Comparison
Compare NBIX & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- JEF
- Stock Information
- Founded
- NBIX 1992
- JEF 1968
- Country
- NBIX United States
- JEF United States
- Employees
- NBIX N/A
- JEF N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- JEF Investment Bankers/Brokers/Service
- Sector
- NBIX Health Care
- JEF Finance
- Exchange
- NBIX Nasdaq
- JEF Nasdaq
- Market Cap
- NBIX 14.4B
- JEF 10.5B
- IPO Year
- NBIX 1996
- JEF N/A
- Fundamental
- Price
- NBIX $144.77
- JEF $55.23
- Analyst Decision
- NBIX Strong Buy
- JEF Buy
- Analyst Count
- NBIX 18
- JEF 4
- Target Price
- NBIX $172.33
- JEF $71.00
- AVG Volume (30 Days)
- NBIX 1.1M
- JEF 2.2M
- Earning Date
- NBIX 10-28-2025
- JEF 09-29-2025
- Dividend Yield
- NBIX N/A
- JEF 2.88%
- EPS Growth
- NBIX 12.44
- JEF 25.06
- EPS
- NBIX 4.19
- JEF 2.92
- Revenue
- NBIX $2,682,700,000.00
- JEF $7,231,501,000.00
- Revenue This Year
- NBIX $23.68
- JEF $5.64
- Revenue Next Year
- NBIX $18.02
- JEF $10.05
- P/E Ratio
- NBIX $34.56
- JEF $19.17
- Revenue Growth
- NBIX 19.61
- JEF 15.68
- 52 Week Low
- NBIX $84.23
- JEF $39.28
- 52 Week High
- NBIX $157.67
- JEF $82.68
- Technical
- Relative Strength Index (RSI)
- NBIX 50.90
- JEF 48.47
- Support Level
- NBIX $145.00
- JEF $52.09
- Resistance Level
- NBIX $148.84
- JEF $59.42
- Average True Range (ATR)
- NBIX 5.31
- JEF 1.96
- MACD
- NBIX -0.33
- JEF 0.61
- Stochastic Oscillator
- NBIX 47.17
- JEF 46.57
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.